Skip to content
value.today

MethylGene Inc.

Total raised
$62 M
2 rounds on record
Latest round
$26 M
Nov 2012
First round on record
Mar 2011
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of MethylGene Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2012$26 MNo. 2$10 to $50 million

MethylGene Inc.: Raise no. 2, Nov 2012

Investors in this round

17 investors had bought by the notice of Nov 21, 2012: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $36 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
$1 million to $5 million
Sales commissions
$1,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Arkadii B. Vaisburg · Executive Officer
  • Charles W. Baum · Executive Officer, Director
  • Gregory B. Reid · Executive Officer
  • Jeffrey M. Besterman · Executive Officer
  • Joseph B. Walewicz · Executive Officer
  • Klaus B. Kepper · Executive Officer
  • Martin Godbout · Executive Officer, Director
  • Rachel B. Humphrey · Executive Officer
  • Henry J. Fuchs · Director
  • Peggy W. Mulligan · Director
  • Peter W. Thompson · Director
  • Rodney W. Lappe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS SECURITIES, LLC (CRD 104059) · New York, New YorkSold in CT, NJ, NY
  • Jefferies & Company, Inc. (CRD 2347) · New York, New YorkSold in CA, CO, CT, IL, MA, NC, NJ, NY, PA

Remarks in the notice

  • On the amounts: “The $9,404,684 amount represents the aggregate exercise price of common share purchase warrants sold in the offering. All amounts stated in U.S. dollars based on an exchange rate of US$1.00 = CDN$0.9973 on November 20, 2012.”

Signed by Klaus B. Kepper, Vice President, Finance, and CFO. Source: SEC Form D, newest notice filed Nov 21, 2012. Read the notice at the SEC.

equity, optionsSEC
Mar 2011$36 MNo. 1$10 to $50 million

MethylGene Inc.: Raise no. 1, Mar 2011

Investors in this round

20 investors had bought by the notice of Nov 16, 2012: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$36 M of $48 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
$1 million to $5 million
Sales commissions
$1,911,765
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Arkadii B. Vaisburg · Executive Officer
  • Charles W. Baum · Executive Officer, Director
  • Gregory B. Reid · Executive Officer
  • Jeffrey M. Besterman · Executive Officer
  • Joseph B. Walewicz · Executive Officer
  • Klaus B. Kepper · Executive Officer
  • Martin Godbout · Executive Officer, Director
  • Rachel B. Humphrey · Executive Officer
  • Henry J. Fuchs · Director
  • Peggy W. Mulligan · Director
  • Peter W. Thompson · Director
  • Rodney W. Lappe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS SECURITIES, LLC (CRD 104059) · New York, New YorkSold in CA, NJ, NY

Remarks in the notice

  • On the amounts: “The $12,714,052 amount represents the aggregate exercise price of the remaining outstanding warrants sold in the offering. The total amount sold includes the value ($43,419) of 200,053 warrants surrendered for the cashless exercise of 282,650 warrants.”

Signed by Klaus B. Kepper, Vice President, Finance, and CFO. Source: SEC Form D and 2 amendments, newest notice filed Nov 16, 2012. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • MethylGene Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Nov 2012).

    SEC Form D (revenue range) · Nov 2012

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2012

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of MethylGene Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by MethylGene Inc.
NameRoleNamed in
Arkadii B. VaisburgExecutive officerNov 2012
Charles W. BaumExecutive officerNov 2012
Gregory B. ReidExecutive officerNov 2012
Jeffrey M. BestermanExecutive officerNov 2012
Joseph B. WalewiczExecutive officerNov 2012
Klaus B. KepperExecutive officerNov 2012
Martin GodboutExecutive officerNov 2012
Rachel B. HumphreyExecutive officerNov 2012
Arkadil B. VaisburgExecutive officerSep 2012
Charles R. GrubsztajnExecutive officerSep 2012
Charles W. BaumDirectorNov 2012
Henry J. FuchsDirectorNov 2012
Martin GodboutDirectorNov 2012
Peggy W. MulliganDirectorNov 2012
Peter W. ThompsonDirectorNov 2012
Rodney W. LappeDirectorNov 2012
Charles R. GrubsztajnDirectorSep 2012
Colin R. MalletDirectorSep 2012
Louis W. LacasseDirectorSep 2012
Peggy R. MulliganDirectorSep 2012
Peter B. ThompsonDirectorSep 2012
Andre ArchimbaudDirectorApr 2011
David J. DrutzDirectorApr 2011
Jay R. MoorinDirectorApr 2011
Louis J. LacasseDirectorApr 2011